公开(公告)号：US20200270356A1

公开(公告)日：2020-08-27

申请号：US16784469

申请日：2020-02-07

申请人： Agenus Inc. ,  Memorial Sloan-Kettering Cancer Center ,  Ludwig Institute for Cancer Research Ltd.

发明人： Marc VAN DIJK ,  Ekaterina V. BREOUS-NYSTROM ,  Volker SEIBERT ,  Gerd RITTER ,  David SCHAER ,  Daniel HIRSCHHORN-CYMERMAN ,  Taha MERGHOUB ,  Hao TANG ,  David A. SAVITSKY ,  Jeremy WAIGHT ,  Nicholas S. WILSON

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  G01N33/68

摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

公开(公告)号：US20200079862A1

公开(公告)日：2020-03-12

申请号：US15781047

申请日：2016-12-02

申请人： Agenus Inc. ,  Memorial Sloan-Kettering Cancer Center ,  Ludwig Institute for Cancer Research Ltd.

发明人： Nicholas S. WILSON ,  Jeremy D. WAIGHT ,  Ekaterina V. BREOUS-NYSTROM ,  Volker SEIBERT ,  Gerd RITTER ,  David SCHAER ,  Daniel HIRSCHHORN-CYMERMAN ,  Taha MERGHOUB ,  Marc VAN DIJK

IPC分类号： C07K16/28 ,  G01N33/68 ,  A61K39/395

摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or diminish, deactivate, or suppress OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., diminishes, deactivates, or suppresses OX40 activity.

公开(公告)号：US20180244793A1

公开(公告)日：2018-08-30

申请号：US15962667

申请日：2018-04-25

申请人： Agenus Inc. ,  Memorial Sloan-Kettering Cancer Center ,  Ludwig Institute for Cancer Research Ltd.

发明人： Ana M. GONZALEZ ,  Nicholas S. WILSON ,  Deninis J. UNDERWOOD ,  Volker SEIBERT ,  Olivier LÉGER ,  Marc VAN DIJK ,  Roberta ZAPPASODI ,  Taha MERGHOUB ,  Jedd David WOLCHOK ,  David SCHAER ,  Gerd RITTER ,  Takemasa TSUJI

IPC分类号： C07K16/28

CPC分类号： C07K16/2878 ,  A61K35/17 ,  A61K2039/507 ,  C07K16/2809 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/502 ,  G01N2333/70578 ,  Y02A50/386

摘要： The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

公开(公告)号：US20220389107A1

公开(公告)日：2022-12-08

申请号：US17662573

申请日：2022-05-09

申请人： AGENUS INC. ,  Memorial Sloan-Kettering Cancer Center ,  Ludwig Insitute for Cancer Research Ltd.

发明人： Nicholas S. WILSON ,  Jeremy D. WAIGHT ,  Dennis J. UNDERWOOD ,  Ekaterina V. BREOUS-NYSTROM ,  Gerd RITTER ,  David SCHAER ,  Daniel HIRSCHHORN-CYMERMAN ,  Taha MERGHOUB ,  Marc VAN DIJK

IPC分类号： C07K16/28

摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies. The antibodies disclosed herein modulate OX40 and/or GITR activity e.g., enhance, activate, induce, reduce, deactivate, or inhibit OX40 and/or GITR activity. The present disclosure also provides methods for treating disorders, such as cancer, autoimmune diseases or disorders, or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and/or human GITR and modulates OX40 and/or GITR activity.